🚀 VC round data is live in beta, check it out!
Anhui Anke Biotechnology Valuation Multiples
Discover revenue and EBITDA valuation multiples for Anhui Anke Biotechnology and similar public comparables like Bavarian Nordic, Nektar Therapeutics, Pfizer India, Wockhardt and more.
Anhui Anke Biotechnology Overview
About Anhui Anke Biotechnology
Anhui Anke Biotechnology (Group) Co Ltd is engaged in the development, manufacture, and sale of pharmaceuticals and health-care products. The Company distributes its product in both domestic and overseas markets. The company operates in more than 30 provinces in China.
Founded
2000
HQ
Employees
767
Website
Financials (LTM)
EV
$2B
Anhui Anke Biotechnology Financials
Anhui Anke Biotechnology reported last 12-month revenue of $400M and EBITDA of $141M.
In the same LTM period, Anhui Anke Biotechnology generated $304M in gross profit, $141M in EBITDA, and $111M in net income.
Revenue (LTM)
Anhui Anke Biotechnology P&L
In the most recent fiscal year, Anhui Anke Biotechnology reported revenue of $388M and EBITDA of $141M.
Anhui Anke Biotechnology expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $400M | XXX | $388M | XXX | XXX | XXX |
| Gross Profit | $304M | XXX | $294M | XXX | XXX | XXX |
| Gross Margin | 76% | XXX | 76% | XXX | XXX | XXX |
| EBITDA | $141M | XXX | $141M | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | 36% | XXX | XXX | XXX |
| EBIT Margin | 32% | XXX | 32% | XXX | XXX | XXX |
| Net Profit | $111M | XXX | $108M | XXX | XXX | XXX |
| Net Margin | 28% | XXX | 28% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Anhui Anke Biotechnology Stock Performance
Anhui Anke Biotechnology has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Anhui Anke Biotechnology's stock price is $1.45.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | -0.9% | XXX | XXX | XXX | $0.06 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAnhui Anke Biotechnology Valuation Multiples
Anhui Anke Biotechnology trades at 5.5x EV/Revenue multiple, and 15.7x EV/EBITDA.
EV / Revenue (LTM)
Anhui Anke Biotechnology Financial Valuation Multiples
As of April 18, 2026, Anhui Anke Biotechnology has market cap of $2B and EV of $2B.
Equity research analysts estimate Anhui Anke Biotechnology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Anhui Anke Biotechnology has a P/E ratio of 21.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 5.5x | XXX | 5.7x | XXX | XXX | XXX |
| EV/EBITDA | 15.7x | XXX | 15.7x | XXX | XXX | XXX |
| EV/EBIT | 17.6x | XXX | 17.9x | XXX | XXX | XXX |
| EV/Gross Profit | 7.3x | XXX | 7.5x | XXX | XXX | XXX |
| P/E | 21.8x | XXX | 22.4x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 20.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Anhui Anke Biotechnology Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Anhui Anke Biotechnology Margins & Growth Rates
Anhui Anke Biotechnology's revenue in the last 12 month grew by 13%.
Anhui Anke Biotechnology's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Anhui Anke Biotechnology's rule of 40 is 48% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Anhui Anke Biotechnology's rule of X is 67% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Anhui Anke Biotechnology Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | 36% | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | 8% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 48% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 67% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 31% | XXX | 30% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 6% | XXX | 6% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 44% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Anhui Anke Biotechnology Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Health & Beauty comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Anhui Anke Biotechnology | XXX | XXX | XXX | XXX | XXX | XXX |
| Bavarian Nordic | XXX | XXX | XXX | XXX | XXX | XXX |
| Nektar Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Pfizer India | XXX | XXX | XXX | XXX | XXX | XXX |
| Wockhardt | XXX | XXX | XXX | XXX | XXX | XXX |
| Ultragenyx | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Anhui Anke Biotechnology M&A Activity
Anhui Anke Biotechnology acquired XXX companies to date.
Last acquisition by Anhui Anke Biotechnology was on XXXXXXXX, XXXXX. Anhui Anke Biotechnology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Anhui Anke Biotechnology
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAnhui Anke Biotechnology Investment Activity
Anhui Anke Biotechnology invested in XXX companies to date.
Anhui Anke Biotechnology made its latest investment on XXXXXXXX, XXXXX. Anhui Anke Biotechnology invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Anhui Anke Biotechnology
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Anhui Anke Biotechnology
| When was Anhui Anke Biotechnology founded? | Anhui Anke Biotechnology was founded in 2000. |
| Where is Anhui Anke Biotechnology headquartered? | Anhui Anke Biotechnology is headquartered in China. |
| How many employees does Anhui Anke Biotechnology have? | As of today, Anhui Anke Biotechnology has over 767 employees. |
| Is Anhui Anke Biotechnology publicly listed? | Yes, Anhui Anke Biotechnology is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Anhui Anke Biotechnology? | Anhui Anke Biotechnology trades under 300009 ticker. |
| When did Anhui Anke Biotechnology go public? | Anhui Anke Biotechnology went public in 2009. |
| Who are competitors of Anhui Anke Biotechnology? | Anhui Anke Biotechnology main competitors are Bavarian Nordic, Nektar Therapeutics, Pfizer India, Wockhardt. |
| What is the current market cap of Anhui Anke Biotechnology? | Anhui Anke Biotechnology's current market cap is $2B. |
| What is the current revenue of Anhui Anke Biotechnology? | Anhui Anke Biotechnology's last 12 months revenue is $400M. |
| What is the current revenue growth of Anhui Anke Biotechnology? | Anhui Anke Biotechnology revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of Anhui Anke Biotechnology? | Current revenue multiple of Anhui Anke Biotechnology is 5.5x. |
| Is Anhui Anke Biotechnology profitable? | Yes, Anhui Anke Biotechnology is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Anhui Anke Biotechnology? | Anhui Anke Biotechnology's last 12 months EBITDA is $141M. |
| What is Anhui Anke Biotechnology's EBITDA margin? | Anhui Anke Biotechnology's last 12 months EBITDA margin is 35%. |
| What is the current EV/EBITDA multiple of Anhui Anke Biotechnology? | Current EBITDA multiple of Anhui Anke Biotechnology is 15.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.